Eli Lilly and Company (NYSE:LLY) Shares Down 3.6% - Time to Sell?

Key Points

• Shares fell 3.6% intraday on higher volume, pressured by short‑term profit‑taking and headline risks including Novo Nordisk’s U.S. launch of an oral Wegovy pill and an Indiana lawsuit over insulin pricing.
• Despite the pullback, Wall Street remains largely bullish with a consensus "Buy" rating and an average price target of about $1,161, as several firms have raised targets in recent weeks.
• Eli Lilly posted a strong quarter—beating EPS and revenue estimates—with FY2025 guidance of $23.00–$23.70 EPS and also raised its quarterly dividend to $1.73, while the stock trades at a high P/E and a market cap near $985 billion.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares dropped 3.6% during mid-day trading on Monday . The stock traded as low as $1,033.38 and last traded at $1,041.7780. Approximately 4,058,538 shares were traded during trading, an increase of 24% from the average daily volume of 3,263,052 shares. The stock had previously closed at $1,080.36.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a "buy" rating in a research report on Wednesday, November 19th. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Guggenheim restated a "buy" rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. UBS Group reaffirmed a "neutral" rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. Finally, The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a "buy" rating in a research report on Monday, December 15th. Five analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $1,161.27.

Eli Lilly and Company Trading Down 3.6%

The company has a market capitalization of $984.88 billion, a P/E ratio of 50.97, a PEG ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business's 50-day moving average price is $1,013.16 and its two-hundred day moving average price is $851.29.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the business posted $1.18 EPS. The firm's revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio is presently 33.86%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of the business. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth $27,000. Vermillion & White Wealth Management Group LLC raised its position in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares during the last quarter. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. grew its position in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company's stock valued at $30,000 after buying an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $31,000. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.